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Lymphangiogenesis: from the pig embryos to cancer
Linfangiogênese: de embriões de suínos ao câncer
Adhemar Longatto Filho1; Maria Duarte2; Fernando C. Schmitt3
The discovery and the comprehension of lymphatic vessels suffered several historical delays and 
setbacks. The inherent anatomical problems slowed down the precise identification of the lymphatic 
system during the development of medical science. Gasparo Aselli, an Italian surgeon and anatomist, 
was the first to describe the lymphatic vessels in 1627 (De Lacteibus sive Lacteis Venis). However, most 
original descriptions that report the morphology of the lymphatic system in different organisms were 
done during the 19th and the 20th centuries. The recent identification of specific lymphatic vasculature 
molecular markers allows a more accurate identification and characterization of the lymphatic system 
evolution in different organs, as well as its role in different pathological conditions, including cancer. 
This study summarizes the current understanding of lymphangiogenesis in tumour progression, as well 
as it presents a review of the promising data regarding the prognostic value of lymphatic density and 
the use of therapeutic lymphangiogenic molecules.
resumo
abstract
A descoberta dos vasos linfáticos e sua compreensão enfrentaram uma série de atrasos e dificuldades 
históricos. As inerentes dificuldades anatômicas retardaram a identificação precisa da rede vascular 
linfática durante o desenvolvimento da ciência médica. Gasparo Aselli, um anatomista e cirurgião italiano, 
foi o primeiro a descrever os vasos linfáticos, em 1627 (De Lacteibus sive Lacteis Venis). Entretanto, a 
maioria das descrições originais que relatam a morfologia do sistema linfático nos diferentes organismos 
foi realizada depois, entre os séculos XIX e XX. A recente identificação de marcadores moleculares 
específicos à vasculatura linfática permite agora identificação e caracterização mais acuradas da evolução 
da rede linfática nos vários órgãos e em diferentes situações, inclusive no câncer. Esta revisão resume 
o conhecimento sobre a linfangiogênese na progressão tumoral, bem como apresenta uma síntese 
dos dados mais promissores em relação ao valor prognóstico da densidade linfática e da utilização das 
moléculas linfangiogênicas como alvo terapêutico.
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Introduction
The lymphatic system is composed of a complex vascular 
network of thin-walled collecting vessels, which drain lymph 
from the extracellular spaces within most organs into larger 
thicker-walled collecting trunks. Physiologic functions of 
lymphatic vessels include the critical draining tissue fluid 
back to the blood circulation of plasma proteins, and cells 
from tissues and organs, particularly during the remodelling 
process. The lymphatic system also contributes to the body 
immune surveillance, absorbing lipids from the intestinal 
tract. Differently from the blood vascular system, the 
lymphatic vasculature does not form a circulatory system; 
the lymph flow is unidirectional from tissues back to blood 
circulation(13). Presently, lymphangiogenesis (the growth 
of newly formed lymphatic vessels) can also be closely 
associated to several pathological conditions, such as 
lymphedema, rheumatoid arthritis, diabetic retinopathy, 
and arteriosclerosis and tumour progression(2). For most 
malignant neoplasms, such as colorectal carcinoma, gastric 
cancer, head and neck squamous cell carcinomas, and 
melanoma, among others, lymphangiogenesis has been 
identified as an important clinical finding and is related to 
poor outcome(17); for others, as breast carcinoma, the real 
meaning of lymphangiogenesis as a prognostic parameter 
is still disputable(10). Importantly, lymphatic markers can 
be used to identify lymphatic vessels also in vascular 
tumours(16).
Malignant cell differentiation programs encode the 
metastatic phenotype, by means of additional genetic or 
epigenetic alterations that determine the tumour cell ability 
to invade. Morphological differences between blood and 
lymphatic vessels will certainly influence the preferential 
escape route, and the peritumoral lymphatics might be 
considered an easy conduit to be invaded by tumour cells 
that are ineffective to traverse blood vessel endothelial 
boundaries(17).
Mechanisms for attracting  
malignant cells
There are active mechanisms for attracting malignant 
cells towards one type of vasculature versus another related 
to inflammatory cells and haematopoietic precursor cells. 
Active recruitment of tumour cells towards endothelial 
lymphatics and stromal cells may occur via epidermal 
growth factor (EGF)-EGF receptor (R)-mediated chemotaxis, 
since macrophages have been found in proximity to 
lymphatic vessels(26). Remarkably, macrophages were 
reported to transdifferentiate into lymphatics in response to 
inflammation in the eye cornea model(11). Complementary, 
lymph node secretion of chemokines, such as straight 
carapace length/curved carapace length (SCL/CCL) 21 and 
CCL1, may attract tumour cells that express receptors CCR7 
and CCR8, respectively(26). Nevertheless, other factors most 
probably induce primary tumours metastization via blood 
or lymphatic vessel.
The lymphatic system is an outstanding conduit for 
neoplastic propagation, since the initial lymphatic vessels 
are greatly outsized when compared with blood capillaries 
and, as advantage for invasion efficacy, do not possess a 
continuous basal membrane. Additionally, the velocity of 
liquid stream inside the lymphatic channels is much lower 
than that observed in blood system that makes possible cell 
preservation and facilitates cell adhesion to escape away 
from lymphatic system; also the composition of lymph is 
extremely comparable to the interstitial fluid, contributing 
in this way towards an increase in cell viability(15).
For many years, the lack of immunohistochemical 
markers to accurately discriminate lymphatic endothelial 
cells (LEC) limited the accurate lymphangiogenesis 
evaluation in cancer setting and metastasis(17). Metastization 
is a multifaceted process involving changes in the expression 
of different genes. The lymphatic invasion comprehends a 
complex interaction of several factors as intratumoral and 
peritumoral interstitial pressures, a number of molecules 
related to cell adhesion molecules, specific micro-anatomic 
structures in lymphatic capillaries and tumour growth within 
lymphatic vessels(13).
The study of lymphatic system at the molecular level, 
analysing the expression profile of different available 
lymphatic markers in the primary tumour, and correlating 
this expression with markers of tumour aggressiveness can 
be of utmost interest for cancer prognostication(20).
Brief homage to Florence Sabin
The commitment of lymphatic sprouting during 
embryogenesis was first describe by Florence Sabin, more 
than a century ago, using pig embryos. She hypothesized 
that primitive lymph sacs originated early in development, 
from a selected fraction of endothelial cells (ECs) that bud 
from the veins. The peripheral lymphatic system extends 
from these primary lymph sacs into the surrounding tissues 
and organs by endothelial sprouting, originating local 
capillaries(13). Huntington and McClure, in 1910, proposed 
an alternative model, where lymph sacs are believed to arise 
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independently in mesenchyme, and afterward ascertain 
the venous connections(13). Almost one century after these 
remarkable investigations, several articles described a plethora 
of cells, genes and proteins that control the different steps 
of embryonic and adult lymphangiogenesis, corroborating 
Sabin’s hypothesis(2, 13). Briefly, the embryonic angioblasts 
are able to develop a primitive vascular net (vasculogenesis) 
that originates the primitive blood vessel conduits. From the 
embryonic veins, lymphatic commitment occurs in part of 
ECs by means of an unknown stimulus. At this point, Prox-1+ 
ECs are capable of initiating the lymphatic differentiation and 
sprouting(13) (Figure 1).
The molecular players of 
lymphangiogenesis
A number of molecules have been recognized as 
essential in the signalling cascade for lymphangiogenic 
sprouting. Lymphangiogenesis comprises a multifarious 
system of greater complexity than supposed in the past. 
Fibroblast growth factor (FGF)-2, platelet-derived growth 
factor-B and hepatocyte growth factor are some of the 
important molecules currently recognized to stimulate 
lymphatic vessel growth(1). Conversely, the essential signals 
for lymphatic differentiation are provided by the homeobox 
transcription factor Prox1 and vascular endothelial growth 
factor (VEGF)-C(2). But there are also other molecules that 
are critical for lymphatic conduit arrangements. Lymphatic 
vessel hyaluronan receptor-1 (LYVE-1) is the first embryonic 
marker of lymphatic endothelial commitment. In adults it 
is downregulated in the large collecting lymphatic vessels 
but remains highly expressed in lymphatic capillaries(7). 
Podoplanin is a transmembrane mucoprotein recognized 
by the recently commercially available D2-40 monoclonal 
antibody. D2-40 reacts with a sialoglycoprotein found in 
lymphatic endothelium and it is supposed to be highly 
efficient in discriminating lymphatic and blood vessels, with 
a great potential for use in clinical practice(14) (Figure 2). 
Although podoplanin function remains unclear, it has 
been already demonstrated that its expression is regulated 
by Prox-1(25). Interestingly, podoplanin is also present 
in mesothelial cells, osteocytes, glandular myoepithelial 
cells, ependymal cells, stromal reticular cells and follicular 
dendritic cells of lymphoid organs. Podoplanin is also 
strongly expressed by granulosa cells in normal ovarian 
follicles, and by ovarian dysgerminomas and granulosa 
cell tumours. Despite the fact that podoplanin is primarily 
absent in normal epidermis, its conspicuous expression in 
squamous cell carcinomas was reported, what strongly 
suggests a potential role of podoplanin in tumour 
progression(25).
Figure 1 – Simplified representation of embryonic human lymphatic vessel differentiation. After the blood vessel net formation, endothelial lymphatic commitment occurs and the 
lymphatic conduits are developed
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Figure 3 – Basic mechanisms of lymphangiogenesis in cancer setting based on VEGF 
family activities. Note that the molecular cross-talk with angiogenic differentiation is 
also observed
The remarkable VEGF family
Neovascularization, as a whole, is largely regulated 
by different members of the VEGF family; angiogenesis 
and lymphangiogenesis, in physiological and neoplastic 
conditions, are directly dependent on the activities of VEGF 
components(2), which are specifically executed by binding 
cellular receptor tyrosine kinases VEGFR-1, VEGFR-2, and 
VEGFR-3, and with different affinity and selectivity among 
them. Additionally, some members of VEGF family also bind 
to neuropilin (Nrp)-1 and Nrp-2. The VEGF family comprises 
seven members: VEGF-A, VEGF-B, placenta growth factor 
(PlGF), VEGF-C, VEGF-D, viral VEGF-E, and snake venom 
VEGF (also known as VEGF-F). Although all members have 
similar structure, there is molecular diversity among the 
subtypes, and several isoforms, such as VEGF-A, VEGF-B, and 
PlGF, which are generated by alternative exon splicing(27). 
VEGF-A is the foremost molecular player in angiogenesis 
and vasculogenesis. Interestingly, VEGF-A was recently 
identified also triggering lymphangiogenic signalling in 
neoplastic setting(4) (Figure 3). VEGF-D is expressed in 
many adult tissues, including the vascular endothelium, 
heart, skeletal muscle, lung, and bowel. VEGF-D may also 
stimulate lymphatic vessel development in adult life in 
response to pathological conditions, including cancer. Both 
VEGF-C and D preferentially bind to VEGFR-3, but they can 
also bind to VEGFR-2 during lymphangiogenesis sprouting. 
Lately, two new VEGF members were identified: VEGF-E, 
which specifically binds to VEGFR-2 and Nrp-1 inducing EC 
mitogenesis and vascular permeability; and the snake venom 
VEGF-F, whose function was not established yet(19).
V
Vascular molecules cross-talking
Newly, it was demonstrated that Prox-1 downstream 
signalling pathway involves fibroblast growth factor 
Figure 2 – D2-40 positive immunoreaction in uterine cervix squamous cell carcinoma 
highlighting lymphatic vessels and lymphatic invasion (400x)
receptor (FGFR) 3, which is upregulated by Prox-1 in 
newly formed lymphatic vessels during embryogenesis 
throughout development(21). This up-regulation is 
mediated at the transcriptional level by a direct binding 
of Prox-1 to the specific sequence elements in the 
FGFR3 gene promoter. Furthermore, FGF1 and FGF2 
bind to the low- and high-affinity receptors in LECs 
promoting migration, proliferation, and cell survival of 
these cells. FGF2-mediated migration is not dependent 
on the VEGF-C/VEGFR-3 signalling pathway, strongly 
suggesting that FGF ligands bind to their receptors in 
LEC, directly playing a role in lymphatic vessel formation. 
The FGF signalling plays an important role in a broad 
range of biological processes of vascular ECs, modifying 
the adhesiveness or the mechanical integrity of the 
extracellular matrix, thereby regulating endothelial 
vascular growth, proliferation, migration, differentiation, 
survival, tubulogenesis, and differentiation of vascular 
system. Recently, we identified a new cross-talk between 
FGF1 and protease-activated receptor (PAR)-1, one of 
the four thrombin receptors, highly expressed in ECs. 
There are emerging evidences that PAR1 modulates cell 
proliferation and motility in physiological cell invasion 
process, suggesting its role in the setting of cancer 
growth and metastasis. Indeed, the overexpression of 
PAR1 is directly correlated with the invasion and the 
metastatic potential of a malignant tumour, such as 
breast carcinoma. In this newly described cross-talk, we 
found that activation of PAR1 signalling mechanisms leads 
to an increase of FGF1 expression and its release. Since 
FGF1 is a well-known mitogen for different cell types, it 
is strongly possible that PAR1 overexpression holds the 
capacity to induce abnormal growth, leading to invasion 
and metastization throughout FGF1 induction, needed 
as pro-angiogenic factor at the early steps of vascular 
modelling(6).
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Translational usefulness of 
lymphatic expression
The overwhelm celebrity of lymphatic vessels in the last 
years are consequence of a great number of remarkable 
standpoints related to the widespread roles of lymphatic-
associated molecules in embryonic development, tissue 
repair and inflammation, and congenital or acquired 
dysfunctions of the lymphatic system, resulting in the 
formation of lymphedema, and vascular malformations. 
Interestingly, several evidences suggest an active role of 
malignant tumours in the induction of intratumoral and 
peritumoral lymphangiogenesis(12). For this reason, the 
evaluation of lymphatic vessel density can bring useful 
information to the tumour management(17).
It is well documented that intratumoral lymphatic 
vessels in tumour xenografts as well as in human tumours 
overexpress VEGF-C or VEGF-D(9). An outstanding so 
far crucial issue is whether intratumoral VEGFR-3/LYVE-
1 positive vessels are functional lymphatics. In fact, 
lymphangiography examination by intravital microscopy, 
after injection of dyes in experimental animal models of 
implanted and spontaneously arising tumours, elegantly 
reveals that lymphatic vessels in the periphery of tumours 
are enlarged and perfused, but compressed and non-
functional within tumour(8). Neoplastic cells growing in 
a restricted area produce mechanical pressure, which 
compresses the weakly newly formed lymphatic channels 
inside the tumour, while at the periphery, excess VEGF-C 
induces LEC growth, which facilitates lymphatic invasion. 
Importantly, absence of functional lymphatics within 
tumours may contribute to interstitial hypertension and 
interfere with the delivery of therapeutic agents. However, 
several data strongly sustain the assumption that enhanced 
numbers of LECs neighbouring the malignant neoplasia 
facilitate metastasis escape to regional lymph nodes by 
providing a greater number of entry sites for the invading 
tumour cells into the lymphatic system(22).
Discussion
A well-accepted protocol to counting the positive 
lymphatic vessels stained by a specific marker is not 
completely established. The number of different proposals 
seriously compromised the reproducibility, and some 
results are conflicting. Additionally, there is also high 
intra- and interobserver variability in lymphangiogenesis 
quantification. Recently, a preliminary effort to standardize 
immunohistochemical lymphangiogenesis assessment was 
reported(23). This purpose is now available and its impact 
as a clinically useful parameter will be known prospectively. 
Certainly, this argument will still remain a contentious matter 
because the method elected to assess lymphatic vessels 
density (LVD) is far from being consensual. Regularly, and by 
analogy to angiogenesis, lymphatic immunostained vessels in 
tumour sections has been evaluated according to Weidner et 
al.(24), where LVD is determined in vascular “hot spots” or areas 
giving the impression, at low magnification, of containing 
numerous stained microvessels at 20x magnification. The 
reproducibility of this method is questionable, since it depends 
on the investigator’s training and experience(23). Therefore, 
Chalkley counting method was considered more useful to 
assess LVD in tumour setting(23). This method involves the use 
of an eyepiece reticule containing 25 randomly positioned 
dots, which is rotated so that the maximum number of 
points is on or within the vessels of the vascular “hot spot”. 
Consequently, as a replacement for counting individual 
microvessels, the overlaying dots are counted, which means 
that the obtained value indicates a relative area occupied 
by lymphatic vasculature, avoiding the subjective decision 
whether adjacent stained structures are separate microvessels 
or not(23). Indeed, stained overlapped-vessels are sometimes 
impossible to be discriminate, for this reason, these conflicting 
structures are assumed as “one” lymphatic unit(16).
As mentioned before, there is still a major disagreement 
about the role of intratumoral versus peritumoral lymphatic 
vessels in solid tumours. Important controversial data have 
been reported showing that peritumoral LVD is more 
importantly associated with the presence of metastases than 
intratumoral LVD(18). Conversely, there are data demonstrating 
that intratumoral vessels are critical for lymphatic metastasis(3). 
Interestingly, it was reported that, in melanomas, the size 
of peritumoral lymphatic vessels is the most significant 
independent factor that correlates with metastasis(5). Possibly 
these apparently contradictory results are not feasible to be 
solved. Recently, Zhang et al.(28) described distinctive signatures 
for specific peptides in lymphatic vessels in different malignant 
and premalignant lesions, hypothesizing that tumour 
development is associated with organ- and stage-specific 
changes in lymphatics and, more particularly, that lymphatic 
vessels exhibit also molecular specificities as tumorigenesis 
progresses. This is an enormous motivating challenge because 
if this assumption is true, the role of lymphatic spread in 
tumour setting might be exhaustively investigated in varied 
series of different types of cancer in order to assess the specific 
characteristics of LVD in each one of them.
Conclusions
LVD is not necessarily indicative of the ongoing 
lymphangiogenesis. To improve this lack of information, 
the use of a cell cycle marker is encouraged, preferentially 
in double-stained reaction. Lymphatic cells proliferation can 
be evaluated by a double immunostaining with antibodies 
directed to a LEC marker such as D2-40 or LYVE-1 associated 
to a marker of proliferating cells, Ki-67 or PCNA. Considering 
the accumulated experience with commercial antibodies, D2-
40 and Ki-67 are two most qualified for this purpose(23).
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Perspectives
The celebrity presently attributed to the study of 
lymphangiogenesis is consequence of the astonishing 
knowledge emerged from the recent studies where 
a number of new molecular signalling was identified 
and correlated to critical physiologic and pathological 
conditions. However, its importance in the metastatic 
spread of tumours still needs more information to be 
adequately elucidated. Additionally, given the importance 
of lymphangiogenesis and its regulators in both lymphatic 
and blood vessels spreading, a number of strategies aimed 
at inhibition of these pathways are under investigation(13).
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